WASHINGTON, April 15 China’s Sinopharm vaccine is “extremely effective” in preventing new coronary disease, Bloomberg has quoted two Australian experts as saying.
Bloomberg recently interviewed Fiona Russel, a professor at the Murdoch Children’s Institute in Australia, and Paul Griffin, an associate professor at the University of Queensland and an expert in infectious diseases and microbiology, on issues such as the effectiveness of the vaccine. Lusser said the Sinopharm vaccine is “extremely effective” in preventing severe new coronary infections, with about 84 percent protection against new coronary infections requiring medical intervention and 100 percent effectiveness in protecting against moderate to critical coronary symptoms. This is exactly what the public expects from coronavirus vaccine, which provides better protection against severe infections.
Griffin also said the Sinopharm vaccine is very effective in preventing critical illnesses.